peptide and peptidomimetic drugs b
1. Overview of Peptides as Pharmaceutical Agents
Biological Properties
Conformational Flexibility:
Peptides and proteins exhibit high rotational freedom due to single bonds in their backbone.
This freedom creates multiple equilibrium conformations, influencing their biological activity.
Structural Dependence:
Primary Structure: Reactivity of amino acid side chains determines initial interactions.
Secondary Structure: Bioactive conformations like α-helices, β-turns, or loops mediate receptor binding.
Degradation and Stability
Proteolytic Metabolism:
Peptides are prone to degradation by proteases, especially at N- and C-termini.
Modifications such as terminal acetylation or amidation improve stability.
Half-Life:
Naturally occurring peptides often have short half-lives (e.g., oxytocin: ~3–5 minutes).
2. Challenges in Peptide Drug Development
Conformational Diversity:
Multiple possible structures can reduce specificity and bioactivity.
Low Metabolic Stability:
Rapid degradation limits their therapeutic use without chemical modifications.
Delivery Challenges:
Poor oral bioavailability due to degradation in the gastrointestinal tract.
Formulation Instability:
Peptides may aggregate or degrade chemically during storage.
3. Peptidomimetics: Synthetic Enhancements
What Are Peptidomimetics?
Synthetic molecules designed to mimic the structure and function of peptides while improving stability, activity, and delivery.
Strategies for Structural Modifications
Incorporation of D-Amino Acids:
Replacing L-amino acids with D-amino acids at key positions prevents recognition by proteases.
Terminal Modifications:
N-Terminus: Acetylation prevents aminopeptidase cleavage.
C-Terminus: Amidation prevents carboxypeptidase activity.
Side Chain Modifications:
Functional group alterations enhance receptor binding and metabolic resistance.
Cyclization:
Enhances structural rigidity and reduces degradation by blocking protease access.
4. Examples of Peptide-Based Drugs
Neurohypophysis Hormones
Vasopressin (ADH):
Regulates water retention and blood pressure.
Stabilized by a disulfide bridge between Cys1 and Cys6.
Modified analogs like Terlipressin:
Additional glycine residues slow hydrolysis, prolonging half-life.
Used to treat septic shock and hepatorenal syndrome.
Oxytocin:
Promotes uterine contractions during labor.
Carbetocin: A synthetic analog with extended half-life for postpartum hemorrhage treatment.
Mimetic Strategies Through Amino Acid Modifications
Vasopressin Analogs:
Desmopressin (DDAVP):
A synthetic analog of vasopressin.
Substitutes D-arginine for L-arginine at position 8.
Lacks pressor effects but retains antidiuretic activity.
Used to treat diabetes insipidus and nocturnal enuresis.
Terlipressin:
Glycine substitutions extend its half-life.
Used in septic shock and hepatorenal syndrome for vasoconstriction.
Oxytocin Analogs:
Carbetocin:
Replaces the disulfide bond with a stable thioether linkage.
Prolongs action compared to oxytocin.
Used to prevent postpartum hemorrhage.
Mimetic of secondary structure
N-Methylation
Definition:
N-Methylation involves replacing the hydrogen on the peptide bond nitrogen with a methyl group (-CH₃).
This modification alters the peptide's backbone conformation and physiochemical properties.
Importance in Mimetic Design:
Enhanced Stability:
Increases resistance to proteolytic degradation by sterically hindering enzyme access.
Structural Constraint:
Reduces flexibility by limiting the conformational space of the peptide.
Mimics β-turns or other secondary structural elements by stabilizing compact conformations.
Improved Lipophilicity:
Enhances cell permeability and oral bioavailability.
Receptor Selectivity:
Alters backbone hydrogen-bonding capacity, potentially improving receptor binding.
2. Introduction of Lactams
Definition:
Lactams are cyclic amides formed by linking the side chain of an amino acid (e.g., lysine or glutamic acid) with the backbone, creating a ring structure.
These can mimic β-turns or loops in peptides.
Role in Mimetic Design:
Secondary Structure Stabilization:
Lactams impose conformational constraints, favoring the formation of β-turns or α-helical structures.
Improved Pharmacokinetics:
Resistance to proteases due to the reduced flexibility of the backbone.
Receptor Binding Enhancement:
Maintains bioactive conformations, increasing binding affinity and specificity.
Mechanisms:
Formed via cyclization between:
The amine group of a lysine side chain and the carboxyl group of an aspartic or glutamic acid.
The backbone amine and the side-chain carboxyl group.
3. Cyclic Peptides
Definition:
Cyclic peptides are peptides whose ends are covalently linked, forming a ring. Cyclization can also occur via side chains (e.g., disulfide bridges or lactam linkages).
Advantages of Cyclization:
Structural Stability:
Reduces flexibility and stabilizes bioactive conformations (e.g., β-turns and α-helices).
Protease Resistance:
Limits access of proteases to cleavage sites, prolonging half-life.
Improved Receptor Affinity:
Pre-organized structures enhance binding interactions with receptors.
Membrane Permeability:
Cyclic peptides often have better lipophilicity and membrane permeability.
5. Gonadotropin-Releasing Hormone (GnRH) Analogues
Function of GnRH
Regulates the release of LH and FSH from the anterior pituitary.
Induces ovulation and stimulates sex steroid production (testosterone and estrogen).
Super-Agonist Design
Enhanced half-life achieved by:
D-Amino Acid Substitutions:
D-Trp in position 6 stabilizes β-turns and resists endopeptidase cleavage.
N-Methylation:
Introduced at key residues to reduce conformational flexibility.
Cyclization:
Stabilizes the bioactive conformation.
Examples:
Triptorelin: Decapeptide with D-Trp substitution for increased potency.
Leuprolide and Goserelin:
Nona-peptides with C-terminal modifications and D-amino acid substitutions.
Clinical Applications
Hormone-sensitive cancers (e.g., prostate, breast).
Ovulation suppression in IVF protocols.
6. Somatostatin and Analogues
Somatostatin Overview
Inhibits growth hormone (GH) secretion.
Contains a disulfide bridge between Cys3 and Cys14, stabilizing the active structure.
Synthetic Analogues
Modified for improved half-life and receptor selectivity:
Octreotide:
D-amino acids (D-Phe, D-Trp) improve resistance to aminopeptidases and endopeptidases.
Terminal modification to alcohol increases stability.
Targets somatostatin receptors (SSR2, SSR5) for neuroendocrine tumor treatment.
Lanreotide:
Similar modifications with enhanced metabolic stability.
Radiolabeled Peptides:
Used in cancer imaging and therapy.
Example: 90Y-DOTA-Octreotide.
7. Integrin Antagonists
Role of Integrins
Transmembrane receptors mediating cell adhesion and signal transduction.
Recognize the RGD (Arg-Gly-Asp) sequence in extracellular matrix proteins.
Peptidomimetic Antagonists
Eptifibatide:
A cyclic peptide targeting platelet integrin αIIbβ3.
Prevents platelet aggregation, reducing cardiac ischemic risks.
Cilengitide:
Targets αvβ3 integrins to inhibit angiogenesis in tumors.
Evaluated as an anti-cancer agent in glioblastoma trials.
8. Incretin Mimetics
Function of Incretins
Hormones like GLP-1 stimulate insulin secretion and lower blood glucose levels.
Rapidly degraded by DPP-4 enzyme.
Synthetic GLP-1 Analogues
Designed to resist DPP-4 degradation and extend half-life.
Exenatide:
Derived from Gila monster saliva; resistant to enzymatic degradation.
Half-life: 2–4 hours.
Liraglutide:
Modified with a fatty acid (C14) for albumin binding, allowing slow release.
Approved for type 2 diabetes and obesity.
Semaglutide:
Weekly dosing achieved by acylation with a C18 fatty acid.
Substitutions prevent enzymatic cleavage, enhancing stability.
Dulaglutide:
A recombinant GLP-1 fused to an IgG Fc fragment, further increasing half-life.
9. Radiolabeled Peptides for Cancer
Radioligands:
Combine peptides (e.g., somatostatin analogues) with radionuclides for imaging or therapy.
90Y-DOTA-Octreotide:
Used for neuroendocrine tumors with SSR2 overexpression.
Mechanism:
Gamma emitters for imaging.
Beta emitters for targeted radiotherapy.